We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+10.27%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$22.8B
AUM Growth
-$510M
Cap. Flow
-$2.26B
Cap. Flow %
-9.9%
Top 10 Hldgs %
40.08%
Holding
187
New
21
Increased
43
Reduced
39
Closed
22

Top Buys

Rank Stock Value
1
DIS icon
Walt Disney
DIS
+$207M
2
ANSS
Ansys
ANSS
+$201M
3
WWD icon
Woodward
WWD
+$192M
4
SWN
Southwestern Energy Company
SWN
+$168M
5
SQSP
Squarespace, Inc.
SQSP
+$130M

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$294M
2
NDAQ icon
Nasdaq
NDAQ
+$256M
3
CRM icon
Salesforce
CRM
+$231M
4
AZN icon
AstraZeneca
AZN
+$188M
5
ARMK icon
Aramark
ARMK
+$187M

Sector Composition

Rank Sector Weight
1 Healthcare 31.84%
2 Technology 13.48%
3 Financials 9.84%
4 Communication Services 6.79%
5 Industrials 6.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONC
126
BeOne Medicines Ltd
ONC
$42.4B
$247K ﹤0.01%
+1,100
New +$198K
IOVA icon
127
Iovance Biotherapeutics
IOVA
$3.76B
$244K ﹤0.01%
26,000
– –
ARQT icon
128
Arcutis Biotherapeutics
ARQT
$3.15B
$242K ﹤0.01%
26,000
– –
CHE icon
129
Chemed
CHE
$7.07B
$240K ﹤0.01%
400
– –
HIMS icon
130
Hims & Hers Health
HIMS
$7.88B
$239K ﹤0.01%
13,000
+3,000
+30% +$53.7K
ELAN icon
131
Elanco Animal Health
ELAN
$12B
$235K ﹤0.01%
+16,000
New +$223K
OSCR icon
132
Oscar Health
OSCR
$9.89B
$233K ﹤0.01%
11,000
– –
RNAM
133
DELISTED
Avidity Biosciences
RNAM
$230K ﹤0.01%
5,000
– –
PACB icon
134
Pacific Biosciences
PACB
$420M
$230K ﹤0.01%
135,000
– –
HQY icon
135
HealthEquity
HQY
$8.81B
$229K ﹤0.01%
2,800
– –
RCM
136
DELISTED
R1 RCM Inc. Common Stock
RCM
$227K ﹤0.01%
16,000
– –
RARE icon
137
Ultragenyx Pharmaceutical
RARE
$2.55B
$222K ﹤0.01%
4,000
-95,000
-96% -$4.84M
INSM icon
138
Insmed
INSM
$27.5B
$219K ﹤0.01%
3,000
-565,000
-99% -$41.7M
ASND icon
139
Ascendis Pharma A/S
ASND
$16.6B
$209K ﹤0.01%
+1,400
New +$189K
NVAX icon
140
Novavax
NVAX
$1.47B
$202K ﹤0.01%
16,000
-361,250
-96% -$4.66M
GERN icon
141
Geron
GERN
$977M
$195K ﹤0.01%
43,000
-16,794,000
-100% -$76.4M
SNDX icon
142
Syndax Pharmaceuticals
SNDX
$1.75B
$193K ﹤0.01%
10,000
– –
COGT icon
143
Cogent Biosciences
COGT
$6.37B
$184K ﹤0.01%
17,000
-408,161
-96% -$3.97M
FOLD
144
DELISTED
Amicus Therapeutics
FOLD
$171K ﹤0.01%
16,000
– –
ALT icon
145
Altimmune
ALT
$605M
$169K ﹤0.01%
27,600
– –
CCCC icon
146
C4 Therapeutics
CCCC
$492M
$160K ﹤0.01%
28,000
– –
ARDX icon
147
Ardelyx
ARDX
$1B
$158K ﹤0.01%
23,000
– –
CGC
148
Canopy Growth
CGC
$472M
$145K ﹤0.01%
30,000
– –
BYND icon
149
Beyond Meat
BYND
$254M
$129K ﹤0.01%
633
– –
SEDA.WS
150
DELISTED
SDCL EDGE Acquisition Corporation Redeemable warrants, each whole warrant exercisable for one share of Class A ordinary share at an exercise price of $11.50
SEDA.WS
$86.6K ﹤0.01%
866,250
– –
4 5
6
7 8

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q3 2024 Portfolio in Review

As of Q3 2024, Thomas Steyer held 187 positions worth $22.8B, down 2.2% from $23.3B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Thomas Steyer withdrew a net $2.26B in Q3 2024, closing 22 positions and reducing 39 holdings. Its most notable exit was AstraZeneca, an estimated $188M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 29% a quarter earlier, followed by Technology and Financials.

Against the trend, Thomas Steyer opened a new position in Woodward worth $198M.

  • Thomas Steyer's largest Q3 2024 buy was Woodward: 1,154,000 shares worth $198M.
  • Thomas Steyer added most to Walt Disney in Q3 2024, an estimated $207M increase.
  • Thomas Steyer's biggest Q3 2024 reduction was UnitedHealth, cutting an estimated $294M.
  • Thomas Steyer fully exited AstraZeneca in Q3 2024, selling an estimated $188M.
  • Thomas Steyer's ten largest holdings make up 40% of its $22.8B portfolio in Q3 2024.
  • Thomas Steyer opened 21 new positions and closed 22 in Q3 2024.
  • Thomas Steyer's portfolio value fell 2.2% quarter-over-quarter to $22.8B.

Based on Farallon Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.